Aktuellt
SENASTE
Ascelia continues to advance the pivotal Mangoral (Orviglance) study, which is also supported by recent publication at the RSNA and positive feedback from a food effect study. Ascelia has also secured a green light from FDA for the approaching phase 2 study combining Oncoral (daily irinotecan chemotherapy) with LONSURF advancing the partnership with Taiho Oncology. Ascelia has delivered on near term objectives recently, in our view.
LÄS MER
